Palabras clave
Cómo citar
Resumen
El Infarto de miocardio Agudo con elevación del segmento ST (IAMCEST), es un importante problema de salud pública en los países desarrollados y comienza a ser un problema cada vez mayor en los países en vía de desarrollo. El reconocimiento precoz del IAMCEST evita muerte por arritmias y permite adoptar estrategias de reperfusión miocárdica que mejoran la sobrevida tanto intra como extrahospitalaria. Muchos pacientes con IAMCEST, son vistos y tratados inicialmente por médicos generalistas, Emergentologos o terapistas, además hay que considerar que en nuestro país un importante número de estos pacientes son internados en terapias intensivas polivalentes, en donde son manejados y tratados por intensivistas. Por lo tanto esta guías persigue un carácter práctico para todos los profesionales médicos, en especial a los médicos intensivista, teniendo en cuenta los distintos niveles de complejidad de las instituciones donde les tocan actuar, asistiendo a estos pacientes.
Citas
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. Eur Heart J. 2016; 37:267-315.
Bazzino O, Charask A, Constantin I, Duronto E, Gonzalez M, et al. Consenso para el manejo de pacientes con SÃndrome Coronario Agudo sin Supradesnivel del Segmento ST (Angina Inestable e Infarto de Miocardio sin elevación del ST. Consenso de la Sociedad Argentina de CardiologÃa. Rev Argent Cardiol 2014; 73(Supl 82): 1 – 44.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary sÃndromes: a report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines developed in collaboration with Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, endorsed by the American Association for Clinical Chemistry. J Am Coll Cardiol 2014; 64:e159-e228
Thygesen K, Alpert J, Jaffe A, Chaitman B, et al. Consenso ESC 2018 sobre la cuarta definición universal de infarto de miocardio. Rev Esp Cardiol. 2019; 72 (1):72.e1.-e27
Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J. 2012; 33:2252–7.
Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J. 2014; 35:552–6.
Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, et al. One-hour ruleout and rulein of acute myocardial infarction using high-sensitivity cardiac troponin T. Arch Intern Med. 2012; 172:1211–8.
Weber M, Bazzino O, Navarro Estrada JL, de Miguel R, Salzberg S, Fuselli JJ, et al. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. Am Heart J. 2011; 162:81–8.
Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).
BMJ. 2006; 333:1091.
de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005; 26:865–72.
Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345-53.
Antman EM, Cohen M, Bernink PJ, Mc Cabe CH, Horacek T, Papuchis G, et al. The TIMI Risk Score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decisión making. JAMA 2000; 284:835-42.
Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57:1920-59.
Gehrie ER, Reynolds HR, Chen AY, Neelon BH, Roe MT, Gibler WB, et al. Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) quality improvement initiative. Am Heart J. 2009; 158:688-94.
Abu-Assi E, Raposeiras-Roubin S, Lear P, Cabanas-Grandio P, Girondo M, Rodriguez-Cordero
M, Pereira-Lopez E, et al. Comparing the predictive validity of three contemporary bleeding risk
scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2012; 1: 222–31.
Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation. 2009; 119:1873–82.
Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, Cameron P, Barger B, Ellims AH, Taylor AJ, Meredith IT, Kaye DM. Air versus oxygen in ST-segment elevation myocardial infarction. Circulation. 2015; 131:2143–50.
Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J 2005; 149:1043–9.
Iakobishvili Z, Cohen E, Garty M, et al. Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care 2011; 13:76–80.
Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ST, Henry T, Hochman JS, Fuchs J, Antman EM, McCabe C, Braunwald E. Effects of prior aspirin and antiischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin inhibition in myocardial ischemia. Am J Cardiol. 1998; 81:678–81.
Cotter G, Faibel H, Barash P, Shemesh E, Moshkovitz Y, Metzkor E, et al. High-dose nitrates in the immediate management of unstable angina: Optimal dosage, route of administration, and therapeutic goals. Am J Emerg Med 1998; 16:219-24.
Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation. 2010; 122:88–95.
Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988; 260:2088–93.
Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, et al. Intravenous beta-blockers in patients with acute coronary syndrome—a meta-analysis of randomized trials. Int J Cardiol. 2013; 168:915–21.
Schroeder JS, Feldman RL, Giles TD, Friedman MJ, DeMaria AN, Kinney EL, et al. Multiclinic controlled trial of diltiazem for prinzmetal’s angina. Am J Med 1982; 72:227-32.
Pepine CJ, Feldman RL, Whittle J, Curry RC, Conti CR. Effect of diltiazem in patients with variant angina: A randomized double-blind trial. Am Heart J 1981; 101:719-25.
Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation. 1988; 78:1–9.
No authors listed. - Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol 1990; 66: 779–85.
Moss AJ, Oakes D, Rubison M, et al. Effects of diltiazem on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. The Multicenter Diltiazem Postinfarction Trial Research Group. Am J Cardiol 1991; 68:429–33.
Perera D, Stables R, Thomas M, et al. Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA 2010; 304:867–74.
Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease:
collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494–502.
Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930–42.
Wallentin L, Becker RC, Budaj A, Cannon CP, et al; for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045–57.
Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic
region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124:544–54.
James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non- invasive management: substudy from prospective randomised Platelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011; 342:d3527.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, et al. TRITOM-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001–15.
Montalescot G, Bolognese L, Dudek D, Goldstein P, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013; 369:999–1010.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of
ischaemic events (CAPRIE). Lancet 1996; 348:1329–39.
Yusuf S, Zhao F, Mehta SR, Chrolavicius S et al. CURE. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494–502.
Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, De Lago A, Wilmer C, et al. CREDO, Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial.
JAMA 2002; 288:2411-20.
Cohen M, Demers C, Gurfinkel EP, Turpie A, Fromell G, et al. A comparison of low-molecular- weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447–52.
Antman EM, McCabe CH, Gurfinkel EP, Turpi AG, Bernenk PJ, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100:1593–601.
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45–54.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354:1464–76.
Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the pentasaccharide in unstable angina (PENTUA) study. J Am Coll Cardiol. 2004; 43:2183–90.
Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial. Circulation. 2005; 111:1390–7.
Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the
ACUITY trial. JAMA. 2007; 298:2497–506.
Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011; 365:1980–9.
Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276:811–5.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.
Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, et al Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009; 360: 2165–75.
Katritsis DG, Siontis GC, Kastrati A, van’t Hof AW, et al. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J. 2011; 32:32–40.
Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, et al. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. Ann Intern Med. 2013; 158:261–70.
Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a metaanalysis of individual patient data. J Am Coll Cardiol. 2010; 55:2435–45.
Lemkes JS, Janssens GN, Van Der Hoeven NW, Van de Ven PM, et al. Timing of revascularización in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial. Eur Heart J. 2019; 40, 283-2091 doi:10.1093/eurheartj/ehy651
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization The Task Force on myocardial revascularization of the European
Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)
Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions Eur Heart J. 2018, 40, 87–165 doi:10.1093/eurheartj/ehy394
La Rosa JC, Grundy SM, Waters DD, Shear C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425–35. 529.
Baigent C, Blackwell L, Emberson J, Holland LE, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670–81. 528.
Cannon CP, Blazing MA, Giugliano RP, Mc Cagg A, et al. Ezetimibe added to statin therapy after
acute coronary syndromes. N Engl J Med. 2015; 372:2387–97. 530.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, et al. Effects of an angiotensin converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342:145–53.
Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547–59.
Granger CB, Mc Murray JJ, Yusuf S, Held P, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting- enzyme inhibitors: the CHARM- Alternative trial. Lancet. 2003; 362:772–6.
Pitt B, Remme W, Zannad F, Neaton J, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348:1309–21. 526.
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364:11–21.
Packer M, Coats AJ, Fowler MB, Katus HA, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001; 344:1651–8.
MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999; 353:2001–7.
La revista no retiene los derechos de reproducción (copyright) por lo que los autores pueden volver a publicar sus trabajos con la sola mención a la fuente original de publicación.